Nost Norvoris 10 earnized Q4, Fy24 Ly24 Liff24 Full Year

Sections of Novo norddisk Seit it on Wednesday after the better pronounced ham company that was expected to raise the seasonal fortune on the fortiliation of wegymit drugs.

Bommoth live at Bommoth's medicine rose 29% every year to 28.23 billion) in fourth forthcoming on the information of information on Tuesday information.

A clean ride of a full-year-full 21% to 100.99 Danish Kroner, also hitting estimates of 99.14 billion.

The drugger sent drugs 107% The increase in the promotion of Webray Sale to 19.87 Donamise (2 2.76 billion) in the three months until the end of December, is required of forecast 20.02 billion.

Maorvo Norris agred on a few to trade 3.1% by 11:15 Am London. Sections of the Blue Dance Competition, Interim, up 1.7% a Protestal Trade was.

Talking to CNCC Wednesday, Head of Lars Grants How much the company can be able to take the US Market before Elia Lilly. The two novo Lilly weight treatments are the convincing stress or elirty But verbal forms have been considered to be the next meeting in extending patients access.

“We really think we can compete in the US market by hand-based handling before launching,” Jørilities we said a Amhhiah.

Jørrentseen, that Novo North Increasing the oral treatment of the US's regulatory consent “with a look at the launch of the next year. Lilly is currently developing a verbal obesity, orformipron, who said the month on a last year, which was early in the early 2026.

“There is a broad general package of different different different types, saying, biormies – also both management and a fixed positiont,” JOrrennTenn add up.

Total selling at the company – who also takes rare disease (which will also take a rare disease That growth was specifically led with the application from North America and Europe, Middle East and Africa.

Growth more slowly at 2025 of between 1625 of 625 to 24% displaying weight and obesity. “A market.”

However, Jørridensen said the minimum production of “stable growth” against a higher basket.

“If you make the mathematical than we contribute to the terms which are based on new patients in 2025 to in 2024,” he said. “As the Foundation becomes larger and greater, the resident grow less interesting with a person who lives with diabetes live with diabetes ) both in the USA “

Harfannah Strereter, Head of Silver and Master Lansdown, said that this may be able to run “for the long-term Health observed benefits.

“Other acceleration depends on less prolonged use issues agreed with health regulators,” she said.

Novo Northiek has a good wave of global demand for glitting glass treatments for GLP-1 viog-1 treatments. GLP-1s, which are the base of a wevovy and competitive Eli Lilly's Zepbund, work by mercking hormone called Fogall-1 Like Gluckon-1, which remove trading.

Investors are now waiting for updates on other sexual drug applicants, including the treatment of the mobormatmatmatmatmatmatmatmatmathatmatmatmatmathatmatmatmat TagriseME test results disappointed Markets in December after they reduce average weight 22.7%, under the 25% Novo before.

Test findings deal with a beat to show only a brief drug to the next bad sister of novoe in a wegy – with Amylin Alog Cagalicin, a Aconk form of pressure loss.

However, positive Early Mode For the ASHCRETH ASYCARTIN ACROGTIN, which adds the same way using the same means of managing the Prancte Pracer Amylin, the highest stock.

No. Norever said Wednesday said he would abolish another check in 2025 with a view to governance agreement in the first quarter of 2026.

Jørrentseen also set out concerns about the happiest of a patch, saying that the data recommends that the treatment suggests is “very safe and also accepting.”

“We make one other test seek to ca … for we think there is more to the delivery of a treatment slightly,” he noted.